P
MDGL icon

Pitcairn’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pitcairn’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-771
Closed -$354K – 336
2025
Q3 		$354K Sell
771
-25
-3% -$9.33K 0.03% 447
2025
Q2 		$241K Sell
796
-183
-19% -$54.5K 0.02% 626
2025
Q1 		$324K Sell
979
-81
-8% -$26.6K 0.02% 560
2024
Q4 		$327K Buy
1,060
+33
+3% +$9.28K 0.02% 559
2024
Q3 		$218K Sell
1,027
-64
-6% -$16.4K 0.01% 671
2024
Q2 		$306K Buy
1,091
+84
+8% +$20K 0.02% 583
2024
Q1 		$269K Buy
+1,007
New +$237K 0.02% 609

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pitcairn's MDGL Position: Q4 2025 in Review

Pitcairn sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 771 shares — an estimated $354K sold.

Pitcairn first reported a position in MDGL in Q1 2024 and held it in 7 quarters. The position peaked at $354K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Pitcairn reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 771 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $354K.
  • Pitcairn first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Pitcairn's Madrigal Pharmaceuticals position peaked at $354K in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.